Rebecca A Marsh

Summary

Affiliation: Cincinnati Children's Hospital Medical Center
Country: USA

Publications

  1. doi request reprint Pre-Transplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab
    Rebecca Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital, Cincinnati, OH Department of Pediatrics, University of Cincinnati, Cincinnati, OH Electronic address
    Biol Blood Marrow Transplant . 2017
  2. doi request reprint Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital, Cincinnati, Ohio
    Pediatr Blood Cancer . 2016
  3. pmc Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 21:1460-70. 2015
  4. doi request reprint Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 20:1641-5. 2014
  5. pmc An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 19:1625-31. 2013
  6. pmc Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immunodeficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Blood 121:877-83. 2013
  7. doi request reprint Flow cytometric measurement of SLAM-associated protein and X-linked inhibitor of apoptosis
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Methods Mol Biol 979:189-97. 2013
  8. doi request reprint Familial hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Ohio 45229, USA
    Ann N Y Acad Sci 1238:106-21. 2011
  9. pmc Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Pediatr Blood Cancer 60:101-9. 2013
  10. doi request reprint Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Blood 116:5824-31. 2010

Collaborators

Detail Information

Publications30

  1. doi request reprint Pre-Transplant Absolute Lymphocyte Counts Impact the Pharmacokinetics of Alemtuzumab
    Rebecca Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital, Cincinnati, OH Department of Pediatrics, University of Cincinnati, Cincinnati, OH Electronic address
    Biol Blood Marrow Transplant . 2017
    ..Additionally, levels correlate with pre-transplant ALC. These results will allow the development of population pharmacokinetic models for precision dosing trials...
  2. doi request reprint Salvage therapy for refractory hemophagocytic lymphohistiocytosis: A review of the published experience
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital, Cincinnati, Ohio
    Pediatr Blood Cancer . 2016
    ..In this review, we summarize the published experience of four therapeutics reported for using at least two patients with HLH refractory to dexamethasone and etoposide or methylprednisolone and ATG...
  3. pmc Experience with Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning Hematopoietic Cell Transplantation in Patients with Nonmalignant Diseases Reveals Good Outcomes and That the Risk of Mixed Chimerism Depends on Underlying Disease, Stem
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 21:1460-70. 2015
    ..We conclude that alemtuzumab, fludarabine, and melphalan RIC HCT offers good results for many patients and that the risk of developing mixed chimerism is influenced by underlying diagnosis, graft source, and alemtuzumab dosing...
  4. doi request reprint Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency/X-linked lymphoproliferative disease type 1
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 20:1641-5. 2014
    ..RIC HCT with alemtuzumab, fludarabine, and melphalan is an effective treatment for patients with XLP1, offering good survival rates regardless of prior disease manifestations, including HLH. ..
  5. pmc An intermediate alemtuzumab schedule reduces the incidence of mixed chimerism following reduced-intensity conditioning hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 19:1625-31. 2013
    ..02). Our findings indicate that intermediate RIC reduces the incidence of mixed chimerism, is associated with a low incidence of upfront acute GVHD, and decreases the need for additional hematopoietic cell products after HCT. ..
  6. pmc Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immunodeficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Blood 121:877-83. 2013
    ..RIC regimens should be pursued with caution and, if possible, efforts should be made to ensure HLH remission before HCT in these patients...
  7. doi request reprint Flow cytometric measurement of SLAM-associated protein and X-linked inhibitor of apoptosis
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Methods Mol Biol 979:189-97. 2013
    ..Proc Natl Acad Sci U S A 95:13765-13770, 1998; Sayos et al. Nature 395:462-469, 1998; Rigaud et al. Nature 444:110-114, 2006). This procedure describes a technique that can be efficiently used to detect SAP and XIAP by flow cytometry...
  8. doi request reprint Familial hemophagocytic lymphohistiocytosis and X-linked lymphoproliferative disease
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Ohio 45229, USA
    Ann N Y Acad Sci 1238:106-21. 2011
    ..Here, we will describe the genetic and functional bases of these diseases, highlight their clinical manifestations, and discuss current diagnostic and therapeutic strategies...
  9. pmc Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Pediatr Blood Cancer 60:101-9. 2013
    ..Salvage therapies have been described only in limited case reports, and there are no large studies of second-line therapies...
  10. doi request reprint Reduced-intensity conditioning significantly improves survival of patients with hemophagocytic lymphohistiocytosis undergoing allogeneic hematopoietic cell transplantation
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Blood 116:5824-31. 2010
    ..0001). We conclude that RIC significantly improves the outcome of patients with HLH undergoing allogeneic HCT...
  11. pmc Patients with X-linked lymphoproliferative disease due to BIRC4 mutation have normal invariant natural killer T-cell populations
    Rebecca A Marsh
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Clin Immunol 132:116-23. 2009
    ..We conclude that XLP due to BIRC4 mutation is not associated with decreased populations of iNKT cells, and that XIAP is likely not a requirement for iNKT cell development...
  12. doi request reprint STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America
    Rebecca A Marsh
    Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Pediatr Blood Cancer 55:134-40. 2010
    ..Mutations in STX11 are responsible for Familial Hemophagocytic Lymphohistiocytosis (FHLH) type 4, a rare primary immunodeficiency which has previously been observed only in patients of Kurdish, Turkish, and Lebanese ethnic background...
  13. pmc XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    Blood 116:1079-82. 2010
    ..We conclude that XIAP deficiency is a unique primary immunodeficiency that is more appropriately classified as X-linked familial hemophagocytic lymphohistiocytosis...
  14. pmc A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency
    Rebecca A Marsh
    Division of Hematology Oncology, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
    Cytometry B Clin Cytom 76:334-44. 2009
    ..Until now, a rapid screening test for XIAP deficiency has not been available...
  15. pmc Reduced-intensity conditioning haematopoietic cell transplantation for haemophagocytic lymphohistiocytosis: an important step forward
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Br J Haematol 154:556-63. 2011
    ..Here we review the current state of the treatment of patients with HLH with allogeneic HCT, highlighting the important steps forward that have been made with reduced-intensity conditioning...
  16. pmc Using flow cytometry to screen patients for X-linked lymphoproliferative disease due to SAP deficiency and XIAP deficiency
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, 3333 Burnet Ave, Cincinnati, OH 45229, USA
    J Immunol Methods 362:1-9. 2010
    ..This review will give a brief overview of the clinical manifestations and molecular basis of SAP deficiency and XIAP deficiency, and will focus on the use of flow cytometry for diagnosis of XLP...
  17. doi request reprint Cytokine Profile of Engraftment Syndrome in Pediatric Hematopoietic Stem Cell Transplant Recipients
    Pooja Khandelwal
    Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 22:690-7. 2016
    ..The observation of elevated IL-1β suggests that engraftment syndrome could be an inflammasome mediated phenomenon. ..
  18. doi request reprint High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients
    Kasiani C Myers
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center and University of Cincinnati, OH 45229, USA
    Biol Blood Marrow Transplant 19:500-3. 2013
    ..We conclude that high-dose steroid therapy if initiated early may reverse VOD of the liver in pediatric HSCT patients, abrogating the need for defibrotide therapy with its associated toxicities and regulatory difficulties...
  19. doi request reprint Peripheral Blood CD38 Bright CD8+ Effector Memory T Cells Predict Acute Graft-versus-Host Disease
    Pooja Khandelwal
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 21:1215-22. 2015
    ..0001). Quantification of CD38 bright CD8+ TEM cells may predict aGVHD in children and young adult HSCT recipients...
  20. pmc A Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell Transplantation
    Adam S Nelson
    Division of Bone Marrow Transplantation and Immune Deficiency Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 22:884-8. 2016
    ..We conclude that a radiation-free RIC regimen results in durable engraftment, acceptable toxicity, and improved overall survival in patients with DC undergoing allogeneic HSCT. ..
  21. doi request reprint Blood, and not urine, BK viral load predicts renal outcome in children with hemorrhagic cystitis following hematopoietic stem cell transplantation
    Hilary L Haines
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
    Biol Blood Marrow Transplant 17:1512-9. 2011
    ..We conclude that the degree of BK viremia, and not viruria, may predict renal, urologic, and overall outcome in the post-HSCT population...
  22. doi request reprint A Prospective Study of Alemtuzumab as a Second-Line Agent for Steroid-Refractory Acute Graft-versus-Host Disease in Pediatric and Young Adult Allogeneic Hematopoietic Stem Cell Transplantation
    Pooja Khandelwal
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 22:2220-2225. 2016
    ..Higher alemtuzumab levels are associated with CR. A real-time dose adjusted alemtuzumab study is needed to further optimize the dose of alemtuzumab in aGVHD...
  23. doi request reprint Alemtuzumab levels impact acute GVHD, mixed chimerism, and lymphocyte recovery following alemtuzumab, fludarabine, and melphalan RIC HCT
    Rebecca A Marsh
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital, Cincinnati, OH
    Blood 127:503-12. 2016
    ..Precision dosing trials are warranted. We recommend a day 0 therapeutic range of 0.2 to 0.4 μg/mL. ..
  24. pmc The successful use of alemtuzumab for treatment of steroid-refractory acute graft-versus-host disease in pediatric patients
    Pooja Khandelwal
    Division of Bone Marrow Transplantation and Immune Deficiency, Cancer and Blood Diseases Institute, Cincinnati Children s Hospital, Cincinnati, OH, USA
    Pediatr Transplant 18:94-102. 2014
    ..We conclude that alemtuzumab is effective for SR-aGVHD in pediatric patients with a tolerable spectrum of complications...
  25. doi request reprint Hemophagocytic lymphohistiocytosis in a female patient due to a heterozygous XIAP mutation and skewed X chromosome inactivation
    Jennifer R Holle
    Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Pediatr Blood Cancer 62:1288-90. 2015
    ..This finding demonstrates that females are susceptible to X-linked forms of HLH through skewed X chromosome inactivation...
  26. doi request reprint Clinical flow cytometric screening of SAP and XIAP expression accurately identifies patients with SH2D1A and XIAP/BIRC4 mutations
    Carrie E Gifford
    Division of Bone Marrow Transplantation and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio
    Cytometry B Clin Cytom 86:263-71. 2014
    ..Flow cytometric methods have been developed to detect the gene products, SAP and XIAP. However, there is no literature describing the accuracy of flow cytometric screening performed in a clinical lab setting...
  27. pmc Hypomorphic mutations in PRF1, MUNC13-4, and STXBP2 are associated with adult-onset familial HLH
    Kejian Zhang
    Division of Human Genetics, Children s Hospital Medical Center, University of Cincinnati College of Medicie, Cincinnati, OH 45229, USA
    Blood 118:5794-8. 2011
    ..We conclude that late-onset familial HLH occurs more commonly than was suspected previously...
  28. doi request reprint A Pharmacokinetic and Pharmacodynamic Study of Maraviroc as Acute Graft-versus-Host Disease Prophylaxis in Pediatric Allogeneic Stem Cell Transplant Recipients with Nonmalignant Diagnoses
    Pooja Khandelwal
    Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 22:1829-35. 2016
    ..All evaluable patients demonstrated functional CCR5 blockade on day 0. Administration of maraviroc is feasible in most pediatric HSCT recipients with good safety and tolerability profile. ..
  29. pmc X-linked lymphoproliferative syndromes: brothers or distant cousins?
    Alexandra H Filipovich
    Division of Bone Marrow Transplantation and Immunodeficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
    Blood 116:3398-408. 2010
    ..In this review, we describe the genetic, clinical, and immunopathologic features of these 2 disorders and discuss current diagnostic and therapeutic strategies...
  30. doi request reprint A Single-Center Experience Comparing Alemtuzumab, Fludarabine, and Melphalan Reduced-Intensity Conditioning with Myeloablative Busulfan, Cyclophosphamide, and Antithymocyte Globulin for Chronic Granulomatous Disease
    Pooja Khandelwal
    Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio Electronic address
    Biol Blood Marrow Transplant 22:2011-2018. 2016
    ..A RIC regimen has lower toxicity but frequently requires interventions to maintain donor chimerism compared with a MAC regimen in CGD...